180 related articles for article (PubMed ID: 21324095)
1. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes.
Chung E; Deyoung L; Brock GB
J Sex Med; 2011 May; 8(5):1472-7. PubMed ID: 21324095
[TBL] [Abstract][Full Text] [Related]
2. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT).
Montorsi F; Brock G; Stolzenburg JU; Mulhall J; Moncada I; Patel HR; Chevallier D; Krajka K; Henneges C; Dickson R; Büttner H
Eur Urol; 2014 Mar; 65(3):587-96. PubMed ID: 24169081
[TBL] [Abstract][Full Text] [Related]
3. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
Montorsi F; Aversa A; Moncada I; Perimenis P; Porst H; Barker C; Shane MA; Sorsaburu S
J Sex Med; 2011 Sep; 8(9):2617-24. PubMed ID: 21707928
[TBL] [Abstract][Full Text] [Related]
5. Nonpalpable scarring of the penile septum as a cause of erectile dysfunction: an atypical form of Peyronie's disease.
Bella AJ; Sener A; Foell K; Brock GB
J Sex Med; 2007 Jan; 4(1):226-230. PubMed ID: 17034410
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
[TBL] [Abstract][Full Text] [Related]
7. Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction.
Porst H; Glina S; Ralph D; Zeigler H; Wong DG; Woodward B
J Sex Med; 2010 Oct; 7(10):3487-94. PubMed ID: 20584129
[TBL] [Abstract][Full Text] [Related]
8. Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction.
Ozturk U; Yesil S; Goktug HN; Gucuk A; Tuygun C; Sener NC; Nalbant I; Imamoglu MA
Ir J Med Sci; 2014 Sep; 183(3):449-53. PubMed ID: 24190613
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.
Cocci A; Cito G; Urzì D; Minervini A; Di Maida F; Sessa F; Mari A; Campi R; Falcone M; Capece M; Morelli G; Cacciamani G; Rizzo M; Polito C; Giammusso B; Morgia G; Verze P; Salonia A; Cai T; Mirone V; Mondaini N; Russo GI
J Sex Med; 2018 Oct; 15(10):1472-1477. PubMed ID: 30245025
[TBL] [Abstract][Full Text] [Related]
10. Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection?
Yang Y; Hu JL; Ma Y; Wang HX; Chen Z; Xia JG; Wang YX; Huang YR; Chen B
Int J Impot Res; 2012 Sep; 24(5):191-5. PubMed ID: 22592761
[TBL] [Abstract][Full Text] [Related]
11. Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily.
Burns PR; Rosen RC; Dunn M; Baygani SK; Perelman MA
J Sex Med; 2015 Mar; 12(3):720-7. PubMed ID: 25615445
[TBL] [Abstract][Full Text] [Related]
12. Tadalafil rehabilitation therapy preserves penile size after bilateral nerve sparing radical retropubic prostatectomy.
Aydogdu O; Gokce MI; Burgu B; Baltacı S; Yaman O
Int Braz J Urol; 2011; 37(3):336-44; discussion 344-6. PubMed ID: 21756381
[TBL] [Abstract][Full Text] [Related]
13. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.
Palmieri A; Imbimbo C; Creta M; Verze P; Fusco F; Mirone V
Int J Androl; 2012 Apr; 35(2):190-5. PubMed ID: 22085227
[TBL] [Abstract][Full Text] [Related]
14. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.
Porst H; Gacci M; Büttner H; Henneges C; Boess F
Eur Urol; 2014 Feb; 65(2):455-64. PubMed ID: 24119319
[TBL] [Abstract][Full Text] [Related]
15. Peyronie's disease: a "triple oxygenant therapy".
Ciociola F; Colpi GM
Arch Ital Urol Androl; 2013 Apr; 85(1):36-40. PubMed ID: 23695404
[TBL] [Abstract][Full Text] [Related]
16. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
17. Oral tadalafil administration plus low dose vasodilator injection: a novel approach to erection induction for penile color duplex ultrasound.
Yang Y; Hu JL; Ma Y; Wang HX; Chen Z; Xia JG; Wang YX; Huang YR; Chen B
J Urol; 2011 Jul; 186(1):228-32. PubMed ID: 21575959
[TBL] [Abstract][Full Text] [Related]
18. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
[TBL] [Abstract][Full Text] [Related]
19. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
20. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors.
Porst H; Brock GB; Kula K; Moncada I; Montorsi F; Basson BR; Kinchen K; Aversa A
J Androl; 2012; 33(6):1305-22. PubMed ID: 22790642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
